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doi:10.1016/j.jtcvs.2006.09.043bjective: We sought to investigate the safety and feasibility of implanting the
umpless interventional lung assist device (Novalung; Novalung GmbH, Hechin-
en, Germany) to the axillary vessels either by means of direct cannulation or
nd-to-side graft interposition and the capability of either type of vascular access to
rovide respiratory support during apneic ventilation in adult pigs.
ethods: Ten pigs were ventilated for 4 hours (respiratory rate, 20-25 breaths/min;
idal volume, 10-12 mL/kg; fraction of inspired oxygen, 1.0; positive end-expiratory
ressure, 5 cm H2O). Thereafter, the interventional lung assist device was surgically
onnected to the right axillary artery and vein by using direct cannulation (n  5)
r end-to-side ringed polytetrafluoroethylene graft interposition (n  5), and ven-
ilatory settings were reduced to achieve near apneic ventilation (respiratory rate, 4
reaths/min; tidal volume, 1-2 mL/kg; fraction of inspired oxygen, 1.0; positive
nd-expiratory pressure, 20 cm H2O). Hemodynamic and intrathoracic volumes and
ung cytokine levels were measured.
esults: Blood flow through the interventional lung assist device was 1.7  0.4
/min or 30%  14% of the cardiac output, and the mean pressure gradient across
he interventional lung assist device was 10  2 mm Hg. The interventional lung
ssist device allowed an O2 transfer of 225.7  70 mL/min and a CO2 removal of
61.7  28.5 mL/min. Although the amount of blood flow perfusing the interven-
ional lung assist device was significantly higher (P  .01) with direct cannulation
2.1  0.3 L/min) compared with that seen in graft interposition (1.3  0.3 L/min),
he latter allowed similar respiratory support with reduced hemodynamic instability.
onclusions: The axillary vessels are a safe and attractive cannulation site for
umpless partial respiratory support. Compared with direct cannulation, graft inter-
osition was equally able to support the interventional lung assist device–driven gas
xchange requirements during apneic ventilation with better hemodynamic stability.
 
ll peripheral artificial lungs (ALs) generated thus far have been attached to
either the groin or neck vessels.1 Unfortunately, this site and the commonly
used high-flow cannulae are unsuitable for clinical long-term or ambulatory
upport because of the potential morbidity (eg, pericannula thrombosis, leak, dis-
odgments, intimal tear, and dissection) and reduced patient compliance (eg, deam-
ulation and mobilization). A hypothetical solution would be to use the axillary
essels, an access increasingly used in cardiothoracic surgery.2-6
The pumpless extracorporeal interventional lung assist device (iLA; Novalung;
ovalung GmbH, Hechingen, Germany) is a new AL powered uniquely by means
f arterial pressure that drives blood flow through a femofemoral shunt created by
ercutaneous arterial and venous cannulation with low-resistance cannulae, thus
voiding the need for a mechanical blood pump. This device allows complete CO2
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 339
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TSemoval and minimal oxygenation and has been success-
ully used thus far as a bridge to lung recovery7,8 and
ransplantation.9 Because of these backgrounds, we inves-
igated the safety and feasibility of attaching the iLA to the
xillary vessels either by means of direct cannulation or
raft interposition and the capability of either access to
rovide respiratory support during apneic ventilation in
igs.
aterials and Methods
en Yorkshire Duroc pigs (Isoquimen S/L, Barcelona, Spain)
eighing 55.1  2.7 kg were used. All animals received care in
ompliance with the “Principles of laboratory animal care” formu-
ated by the National Society for Medical Research and the “Guide
or the care and use of laboratory animals” prepared by the
nstitute of Laboratory Animal Resources, National Research
ouncil, and published by the National Academy Press, revised 1996.
he study was approved by the Animal Care and Use Committee of
he University of Barcelona (Project N-0001-61399030-F).
tudy Design
nimals were ventilated with volume control (Servo 900D; Sie-
ens, Munich, Germany) for 4 hours with the following respira-
ory settings: respiratory rate, 20 to 25 breaths/min; tidal volume
TV), 10 to 12 mL/kg; fraction of inspired oxygen (FIO2), 1.0; and
ositive end-expiratory pressure, 5 cm H2O. After this observation
eriod (4 hours), the right axillary artery and vein were surgically
onnected to the iLA through either direct cannulation (group 1,
 5) or graft interposition (group 2, n  5), and the ventilator
arameters were modified to achieve a near-static (or apneic)
entilation, targeting a respiratory rate of 4 breaths/min and a TV
f 1 to 2 mL/kg while maintaining the same FIO2 and gradually
ncreasing the positive end-expiratory pressure to 20 cm H20. The
tudy was completed after this 8-hour period. Assignment to either
roup was aleatory and independent of the diameter or rigidity of
he vessel.
nesthesia and Monitoring
nimals were premedicated with intramuscular azaperone (4 mg/
g) and intravenous thiopental (10 mg/kg) and relaxed with intra-
enous rocuronium (6 mg · kg1 · h1). Orotracheal intubation
as obtained through a 7.5F endotracheal tube under broncho-
copic guidance. Anesthesia was maintained by means of contin-
Abbreviations and Acronyms
AL  artificial lung
ARDS  adult respiratory distress syndrome
AVCO2R  arteriovenous extracorporeal CO2 removal
CO  cardiac output
FIO2  fraction of inspired oxygen
IL  interleukin
TNF-  tumor necrosis factor 
TV  tidal volumeous infusion of fentanyl (1 g · kg1 · h1) and propofol t
40 The Journal of Thoracic and Cardiovascular Surgery ● Febr3-5 mg · kg1 · h1) until the study end. Antibiotic therapy
ncluded 2 g of intravenous cefazolin at induction of anesthesia.
nimals were instrumented with an arterial pressure line (5F)
laced transcutaneously in the right femoral artery (PiCCO plus;
ulsion Medical Systems, Munich, Germany) and several periph-
ral venous catheters and a Swan-Ganz catheter (Edwards Life-
ciences, Munich, Germany) placed transcutaneously in the left
nternal jugular vein. Peripheral oxygen arterial saturation was
ontinuously monitored with a pulse oximeter (BCI, Inc, Wauke-
ha, Wis) placed at the pig’s tail and another probe placed on the
ight arm. Urine output was continuously monitored by placement
f a percutaneous bladder catheter. Temperature was maintained at
7°C with heaters and blankets. Intravenous 0.9% NaCl fluids and
asoactive drugs were given if systemic systolic arterial pressure
ecreased to less than 100 mm Hg, as was intravenous atropine
0.5-1 mg) if heart rate was less than 50 beats/min.
LA Implantation Technique
nder sterile conditions, a 6- to 10-cm incision over the equivalent
f the human right deltopectoral groove allowed easy exposure and
ncirclement by an umbilical tape of the subclavian and axillary
essels, taking care to preserve the infrascalenic portion of the
rachial plexus. This site was used because of our previous hemo-
ynamic and surgical experience.10 Proximal and distal control of
he axillary artery was gained, and the umbilical tape was passed
hrough a tourniquet. After systemic heparinization (20 IU/kg),
emoral artery clamps were used proximal and distal to the can-
ulation or implantation site.
In group 1, after a transversal arteriotomy, the axillary artery
15F) and vein (17F) were cannulated with specially designed,
hort, straight, low-resistance cannulae (Novaport; Novalung
mbH, Hechingen, Germany; Figure 1). The tourniquets were
ightened and secured, flow was evaluated on the basis of ante-
rade or back bleeding, and, if adequate, the cannulae were
lamped. The distal arterial clamp was left in place until the end of
he study period, and the perfusion of the distal arm was controlled
linically and with the previously placed pulse oximeter. In group
a 1- to 2-cm vertical arteriotomy and venotomy were created, and
igure 1. Photograph showing a direct cannulation of the axillary
rtery and vein in the right deltopectoral groove.wo 8-mm ringed polytetrafluoroethylene (Jotec GmbH, Hechin-
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G
TSen, Germany) grafts of 3 cm in length were sewn onto the artery
nd vein in an end-to-side fashion by using vascular parachute
echniques and 5-0 or 6-0 polypropylene sutures (Prolene; Ethicon,
nc, Somerville, NJ; Figure 2) and ultimately connected to the iLA
ystem through silicone straight 1/4  3/8 rubber connectors
Novalung GmbH). The iLA device and tubing system were com-
letely deaired and filled with normal saline solution (approxi-
ately 240 mL). Finally, the tubes were connected to the cannulae
r silicone connectors, and the proximal clamps were slowly
emoved to create a peripheral arteriovenous shunt. A sweep gas
ube providing pure O2 (6-12 L/min) was connected to the iLA and
laced at the bedside (Figure E1). Functional control was achieved
hrough a monitor (Blood Flow Monitor, Novalung GmbH), which
alculates blood flow through the system by using an ultrasonic
ow probe (NovaFlow System, Novalung GmbH) placed at the
enous cannula. iLA malfunction was defined as a driving blood
ow of less than 0.5 L.
The capability of the iLA to provide additional O2 was mea-
ured by calculating the O2 content of blood entering and exiting
he device and multiplying the difference by the flow rate through
he device, according to the following formula:
xygen transfer (mL ⁄ min)
 [(Oxygen content as volume %)
 10 dL ⁄ L] iLA flow rate (L ⁄ min)
he arteriovenous extracorporeal CO2 removal (AVCO2R) pro-
ided by the iLA was calculated as follows:
VCO2R (mL ⁄ min)
 CO2 content in the inflow arterial cannula
 CO2 content in the venous outflow cannula
(mL CO2 ⁄ mL blood)
 Blood flow iLA (L ⁄ min) 10
emodynamics and Lung Function
he following hemodynamic variables were measured hourly
igure 2. Photograph showing graft interposition to the axillary
rtery and vein in the right deltopectoral groove.monitor, Hewlett Packard model 685): heart rate, cardiac output c
The Journal of ThoracicCO), cardiac index, mean arterial pressure, mean pulmonary
rterial pressure, pulmonary capillary wedge pressure, central ve-
ous pressure, systolic index, systolic volume, systemic vascular
esistance, pulmonary vascular resistance, left ventricular systolic
ork, right ventricular systolic work, and body temperature
hrough the Swan-Ganz catheter. PiCCO allowed us to measure the
xtravascular lung water volume, intrathoracic blood volume, and
entricular contractibility. Ventilator parameters, including minute
entilation, lung compliance, and peak inspiratory pressure, and
rterial and venous blood gases were evaluated hourly as well.
ung Cytokine Assays
he left lung was lavaged with 40-mL aliquots of sterile saline
olution (0.9% NaCl) instilled through the bronchoscope’s channel
nd subsequently aspirated manually before intubation and every
our thereafter. Tumor necrosis factor  (TNF-), interleukin (IL)
, and IL-8 levels were measured in bronchoalveolar lavage su-
ernatants by using an enzyme-amplified sensitivity immunoassay
ased on the quantitative immunometric sandwich enzyme immu-
oassay technique (Medgenix Diagnostics, Fleurus, Belgium) and
erSeptive (Framingham, Mass). Normal concentration values in
ur laboratory are as follows: TNF-, 25 to 120 g/mL; IL-6, less
han 39 g/mL; and IL-8, less than 62 g/mL.
istopathologic Features
nimals were killed 4 hours after iLA implantation or if the
nimal’s condition was deteriorating, by using an intravenous
olus of fentanyl and propofol and potassium chloride (40 mEq).
ystemic heparin (100 IU/kg) was also given to avoid postmortem
hrombus formation. The lung tissue samples of each lobe were
issected and placed in formalin for 18 hours and then in 70%
ethanol for 24 hours. Paraffin-embedded lung sections measuring
m were mounted on slides and stained with hematoxylin and
osin. Each section was evaluated to search for acute/chronic
nterstitial or alveolar inflammation, alveolar edema, and the pres-
nce of macrophages, desquamative cells, or polymorphonuclear
ntra-alveolar cells. Also, infarction or clots in the lung were
valuated. Cannulated or grafted vessels were evaluated for the
resence or absence of emboli or thrombi or intimal injury.
tatistical Analysis
ontinuous variables were compared by using the independent-
amples t test. The odds ratio was calculated to perform between-
roup comparisons of categoric variables. Results are presented as
eans  standard error of mean. Analyses were made with the
PSS package (version 7.0; SPSS, Inc, Chicago, Ill).
esults
ll animals completed the study protocol. Graft interposi-
ion was more time consuming (21  5 minutes) than direct
annulation, whereas the latter was technically more de-
anding, especially during the introduction and anterograde
lacement of the arterial cannula in the brachiocephalic
rtery. Except for 1 dislodgement and temporary malfunc-
ion of 1 arterial cannula, there were no other neurovascular
omplications.
and Cardiovascular Surgery ● Volume 133, Number 2 341
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3
G
TSThe overall blood flow perfusing the iLA was 1.7  0.4
/min or 30% 14% of the CO (7.2 2.6 L/min), and iLA
eclamping induced a peripheral arteriovenous shunt effect
Table E1) that was well tolerated clinically. The mean
esistance of the iLA was 10  2 mm Hg. The iLA device
upported a mean O2 transfer and AVCO2R of 225.7  70
L/min and 261.7  28.5 mL/min (Figure 3), respectively,
nd permitted a significant reduction of the ventilatory
ettings to reach a near-apneic ventilation status (Table 1).
irect cannulation permitted a significantly higher arterial
nflow through the iLA device than graft interposition (2.1 
.3 vs 1.3  0.3, P  .01, Figure E2) throughout the entire
tudy period, whereas the latter provided similar iLA-driven
espiratory support (Table 2) and more hemodynamic sta-
ility (Table E2) during apneic ventilation.
Figure 4 shows the evolution of the bronchoalveolar
avage concentrations of lung cytokines during the different
entilation modes. Final pathological examinations were
ormal in all specimens.
iscussion
resently, a long-term intracorporeal AL remains a dream,11
nd recent progress1 suggests a high likelihood of success
or ambulatory and extracorporeal devices that can be
witched in and out, as in a dialysis setting, with11 or
ithout1 an integrated pumping system. However, the clin-
cal feasibility and advantages of pumpless devices to pro-
ide effective gas exchange when placed in parallel with the
ative circulation, either centrally (pulmonary artery to left
igure 3. Correlation of O2 transfer and arteriovenous CO2 re-
oval (AVCO2R) to the blood flow perfusing the interventional
ung assist device during apneic ventilation.trium) or peripherally (usually femoral artery and vein, (
42 The Journal of Thoracic and Cardiovascular Surgery ● FebrVCO2R), have been demonstrated experimentally and
linically.7,12-16
The iLA device is a relatively new, commercially avail-
ble, low-resistance membrane lung designed for pulsatile
lood flow with tight diffusion membranes and a protein
atrix coating, incorporating a gas exchange surface of 1.3 m2.
ecause the mean pressure gradient of the Novalung can-
ulae and device is approximately 7 mm Hg with a blood
ow of between 0.5 and 2.5 L/min, it can be powered solely
y the mean arterial pressure when placed peripherally
hrough an arteriovenous shunt created by percutaneous
rterial and venous cannulation with low-resistance cannu-
ae.8 Because oxygenation is essentially uncoupled from
O2 removal, the iLA has successfully been used to allow
nd optimize advanced lung protective ventilation strategies
eyond ARDSnet17 in patients with adult respiratory dis-
ress syndrome (ARDS)7 and CO2 retention syndromes
ithout ventilator-associated lung injury, in recovery from
ung injuries, and as a bridge to transplantation.8,9 The iLA
as also been used in general thoracic patients as intraop-
rative respiratory support or to treat postoperative noncar-
iogenic ARDS (personal communication). However, be-
ause of its simplicity, low invasiveness, no need for pump
upport, and access through peripheral vessels, the iLA
ight have much wider application in an ambulatory con-
guration as a bridge to transplantation or as an alternative
o transplantation (long-term palliation). The minimal O2
ransfer is an obvious limitation of the arteriovenous attach-
ent mode, but hypoxia can be treated by means of low-
ow O2 supplementation to permit O2 diffusion across the
esting native lungs, either as apneic oxygenation18 or
yperoxygenation.19
Thus far, extracorporeal ALs have used either the neck
ABLE 1. Average ventilatory variables during initial ven-
ilation (4 hours) and apneic ventilation under interven-
ional lung assist device support (4 hours)
ariables
Initial ventilation
without iLA support
Apneic ventilation
with iLA support P value
V (mL) 527 62 98 15 .001
R (beats/min) 21.9 2.8 4  0.3 .001
V (L /min) 12.1 1.6 0.67 0.5 .001
IP (cm H2O) 23.4 2.6 22 2.1 NS
EEP (cm H2O) 5.1  0.3 20 2 .001
aO2/FIO2 479.5 81.3 328.2 120.7 .001
aCO2 (mm Hg) 40.8 7.5 51.6 4.1 .001
C (mL /cm H2O) 51  9.1 95.7 15.2 .001
LA, Interventional lung assist device; TV, tidal volume; RR, respiratory rate;
V, minute volume; PIP, peak inspiratory pressure; NS, not significant;
EEP, positive end-expiratory pressure; PaO2 /FIO2, arterial oxygen tension/
raction inspired oxygen; PaCO2, arterial carbon dioxide tension; LC, lung
ompliance [(TV/Plateau pressure)  PEEP)].carotid artery–internal jugular vein) or groin (femoral ar-
uary 2007
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G
TSery and vein) circulation as the site of implantation, both of
hich are eventually inadequate for long-term use or in
mbulatory patients. In this sense the axillary vessels might
epresent a valid alternative and provide several advantages.
irst, the subclavian or axillary vein is a routine cannulation
ite in an ambulatory setting. Second, the axillary artery is
arely and less diseased than the iliofemoral vessels, benefits
rom a rich collateral blood flow that reduces the hazards of
schemia in the upper extremity, and has already been
eneficial for different cardiac open procedures2-6 and once
igure 4. Evolution of bronchoalveolar cytokines during initial
entilation (0-4 hours) and apneic ventilation (4-8 hours). The
nitial increase of tumor necrosis factor  (TNF-; P  .05),
nterleukin 6 (IL-6 ; P < .005), and interleukin 8 (IL-8 ; P < .05)
oncentrations during the first phase attenuated to normal values
uring apneic ventilation and use of the interventional lung assist
evice. Normal concentrations in our laboratory are as follows:
NF-, 25 to 120 g/mL; IL-6, less than 39 g/mL; and IL-8, less
ABLE 2. Differences in respiratory variables between dire
nder interventional lung assist device support
Variables Direct cannulation
TV (mL) 97 1.9
RR (beats/min) 4 0.3
MV (L /min) 0.6 0.2
PIP (cm H2O) 23.5 2.4
PEEP (cm H2O) 22.1 4.3
PaO2/FIO2 350.4 111.1
PaCO2 (mm Hg) 53.6 8.3
LC (mL /cm H2O) 100.9 8.5
BFR (L /min)/% CO 2.1 0.3/30.8 1
O2 transfer (mL /min) 179.8 48
AVCO2R (mL /min) 340 28
V, Tidal volume; NS, not significant; RR, respiratory rate; MV, minute vo
aO2 /FIO2, arterial oxygen tension/fraction of inspired oxygen; PaCO2, arteria
FR, blood flow rate through the device; CO, cardiac output; AVCO2R, artphan 62 g/mL.
The Journal of Thoracicor extracorporeal respiratory life support.20 Moreover, it
an be safely cannulated either directly or through end-to-
ide graft interposition.6
In the present study we investigated the safety and
fficacy of the axillary vessels as a vascular access site
or partial extracorporeal respiratory support. The pre-
ented results demonstrate that the iLA connected
hrough an end-to-side graft interposition to the axillary
rtery and subclavian or axillary vein provides respira-
ory support similar to direct cannulation during apneic
entilation. This finding might have various different
linical advantages; for example, tunneled and high-vol-
me cannulae placed over longer periods of time are
ore likely to dislodge or induce brachiovascular inju-
ies, can lead to infectious complications, and are less
atient friendly. On the contrary, cannulation of a graft
ttached to the axillary artery might avoid the technical
itfalls described clinically with direct cannulation5,6 and
reatly simplifies decannulation or device exchange. In-
eed, the only disadvantages appear to be the extra time
equired at the onset to anastomose the graft to the artery
approximately 20 minutes), the occasional bleeding
rom the suture line, and, last but not least, that the use of
he prosthetic graft anastomosed to the artery is more
xpensive than the provided cannulae and might become
nfected. However, these pitfalls could be avoided by
lacing the arterial cannula into a saphenous vein graft21
hat had been previously anastomosed end-to-side to the
xillary vessels, and this would result not only in no extra
ost but also in an unlimited availability and more
emostasis.
Axillary arterial cannulation powered significantly (P 
001) more blood flow (2.1  0.3 vs 1.3  0.3 L/min)
hrough the iLA than graft interposition, and this might be
nnulation and graft interposition during apneic ventilation
Graft interposition P value
99.4 9.1 NS
4  0.3 NS
0.5 0 NS
21.3 1.9 NS
20.3 3.5 NS
307 148.6 NS
49.1 9.7 NS
95.4 3.6 NS
1.3 0.3/13.3 10 .001
123.7  51.9 NS
223 26 .05
; PIP, peak inspiratory pressure; PEEP, positive end-expiratory pressure;
on dioxide tension; LC, lung compliance [(TV/Plateau pressure)  PEEP)];
nous carbon dioxide removal.ct ca
2
lume
l carbartly explained by the technique itself and because we did
and Cardiovascular Surgery ● Volume 133, Number 2 343
ct
u
w
d
i
s
s
b
n
c
e
m
o
t
a
v
i
d
i
s
a
T
b
1
t
m
d
h
a
t
A
a
p
a
s
3
p
(
t
i
t
d
a
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
General Thoracic Surgery Iglesias et al
3
G
TSlamp the artery distal to the cannulation site during inves-
igation. However, a long-term direct arterial cannulation is
nfeasible clinically, and an arterial graft interposition
ould have the advantage that it would still permit optimal
istal arm perfusion, thus minimizing the risks of ischemic
njury of the arm and, ultimately, avoiding a compartment
yndrome on reperfusion5 and allowing more hemodynamic
tability because only about less than 15% of the CO would
e diverted to it. In any case this blood flow difference did
ot affect the iLA graft-driven AVCO2R (223  26 L/min)
apacity or O2 transfer, which are in line with the basal
xchange requirements of an adult patient (200 and 240
L/min, respectively, at a CO of 4-6 L/min). Because no
ther respiratory variables were different during apneic ven-
ilation, one might speculate that graft interposition in the
xillary vessels could provide peripheral gas exchange in a
ariety of clinical situations in which hemodynamic stabil-
ty and early mobilization, ambulation, and extubation are
esired.
The bronchoalveolar lavage cytokine responses observed
n this study cannot be ultimately interpreted because of the
mall samples. However, one might speculate that the rapid
ttenuation of the inflammatory response (IL-6, IL-8, and
NF-) observed during the initial ventilation strategy can
e explained by the fact that the combination of apneic (TV,
-2 mL/kg) ventilation and iLA affords a better lung pro-
ection and minimizes more lung overdistention, recruit-
ent, and derecruitment than the ARDSnet ventilation mo-
us (TV, 6-12 mL/kg).17 This in turn confirms previous
uman studies in which low (6 mL/kg) TV ventilation was
ssociated with a more rapid attenuation of the inflamma-
ory response in patients with acute lung injury and
RDS.22,23
In conclusion, the present study demonstrates that the
xillary vessels are a safe cannulation site for extracorporeal
eripheral partial respiratory support and that the iLA, once
ttached to this paracorporeal site, provides, with minimal
urface area (1.3 m2) and shunt blood flow (approximately
0% of the CO) requirements, an almost total removal of the
roduced CO2 and permits near-static or apneic ventilation
TV, 1-2 mL/kg). The minimal shunt blood flow (15% of
he CO) requirements, similar gas exchange capability, and
mproved hemodynamic stability of graft interposition make
his vascular access modality clinically more attractive than
irect cannulation and might represent a further step toward
mbulatory long-term AL support.
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TSiscussion
r Michael S. Mulligan (Seattle, Wash). This work adds to the
iterature underscoring the point that pumpless atrioventricular
upport of gas exchange has a place in the care of the critically ill.
O2 removal and O2 transfer are physiologies that can be uncou-
led and supported independently. I have several questions. The
ost consistent benefit demonstrated in the experience with the
ffinity and NovaLung devices relates to improved outcomes with
O2 removal in patients with ARDS. Entirely adequate rates of
O2 removal are achievable with device flows as low as 800 to
000 mL or 10% to 15% of CO. Therefore why is it necessary or
esirable to divert 30% to the CO through the device?
The oxygen transfer rate across this device seems high. One
ould assume that to achieve that, the arterial blood inflow must
e desaturated in the range of 65% or so. However, the low-
requency positive-pressure ventilation that you used and not ap-
eic ventilation, in fact, is highly effective at maintaining oxygen-
tion, as per the work of Kolobo. One would expect saturations in
hat paradigm in the range of 85% to 95%. Can you explain how
uch high levels of O2 transfer were achieved across this device?
f flows adequate for CO2 removal are attainable with small
ercutaneous cannulae, what is the real advantage to axillary
rterial dissection and potential grafting in what is likely to be a
ritically ill and nonambulatory population? Finally, the duration
f 4 hours on the device might not reflect a clinically useful
nterval. Similarly, comparing bronchoalveolar lavage cytokine
ontent from animals that had direct versus graft cannulation does
ot assess the inflammatory response attributable to pumpless
upport of gas exchange itself. Do you have any data from animals
efore and after the institution of support, allowing each animal to
erve as its own control? Thank you for sending me the manuscript
nd for continuing to help advance this important field.
Dr Macchiarini. As senior author, I take the privilege to
nswer the questions. Thank you for the questions. Thirty percent
f the CO is the normal range of the output that you might power
hrough the iLA when you put it on the femoral vessels, and this
as been used in almost more than 1000 patients thus far. There-
ore what we decided is to have an alternative, to in fact have less
O through the iLA and, as a matter of fact, through the graft
nterposition. We were able to flow only 10% of the CO, which
as approximately 1.2 L/min.
I cannot remember all the questions, but the last one was why
e chose this limited time of investigation. First of all, there are
rticles suggesting that 4 hours is enough at the given tidal volume
f 10 to 12 mL/kg to induce a lung injury, and therefore we used
The Journal of Thoracichat time frame. Thereafter, the second 4 hours of observation time
as simply because there is clinical evidence that the lung cyto-
ine response induced in patients with ARDS can be reversed
ithin 3 days, and probably you, better than I, know that in an
nimal setting this time corresponds to the 3 days in the clinical
ssue.
I cannot remember the other questions.
Dr Joseph B. Zwischenberger (Galveston, Tex). There are a
ouple of key points that the discussant brought up that still need
o be addressed. First of all, arteriovenous CO2 gas exchange has
een existent for about 10 to 15 years, and many of us have been
orking on this, and, as you alluded to, there is more than a
000-patient experience in Europe with the NovaLung. However,
here are 2 camps. One camp is the high-flow camp that wants to
et 20% to 30% of CO and access the femoral vessels with a large
annula (18F to 20F), and they have about a 25% complication rate
ith vascular access. Then there is the low-flow camp, to which I
elong, that goes for about 10% to 15% of CO and can use a 12F
o 14F cannula in which the complication rate is less than 5%. If
ou use the low-flow strategy, you can accomplish total CO2
emoval, but you do not contribute significantly to oxygenation
nd therefore rely on the native lungs. The key question in this
resentation is why do you report such large O2 transfer numbers,
nd why do you think such large flows are necessary, especially in
n animal that has normal native lungs and can accomplish oxy-
enation without difficulty?
Dr Macchiarini. Thank you, Joe.
The issue with the cannula, and you know better than I, is not
he volume. It is the resistance that they have. Therefore we might
alk about that in a later session. However, the O2 transfer that we
ad is probably because, at odds with your studies, we use an FIO2
f 1 and not lower because we did not want to have 2 different
arameters change in the same study, and this might explain why
e had more. Therefore because oxygenation was done through
he native lungs and not through the oxygenator, I think this could
robably explain this, keeping the FIO2 at 100% at the second
hase, the high oxygen transfer.
Dr Mulligan. Are you saying that your O2 transfer was attrib-
table to the native lung and not the device? That was not clear in
he manuscript. Therefore that is what you are saying, that you
upported CO2 scrubbing and O2 transfer independently, one with
he device and one with the native lung with low-frequency
ositive-pressure ventilation? Is that correct?Dr Macchiarini. Exactly.
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G
TSFigure E1. Photograph showing graft interposition to the axillary artery and vein in the right deltopectoral groove
and their connections to the rubber connectors and the interventional lung assist device.
Figure E2. Comparison of the type of vascular access and blood flow perfusing the interventional lung assist
device.45.e1 The Journal of Thoracic and Cardiovascular Surgery ● February 2007
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TSABLE E1. Pigs hemodynamic during initial ventilation (4 hour) and apneic ventilation under interventional lung assist
evice support (4 hours)
ariables Initial ventilation without iLA support Apneic ventilation with iLA support P value
O (L/min) 6.8 3 7.7  3 NS
AP (mm Hg) 97.2 17.7 79.7 11.3 .001
PAP (mm Hg) 28.7 4.7 41.1  6.5 .001
VR (dyne/cm5) 1072.6 370.6 721.7 383.4 .001
VR (dyne/cm5) 151.1 137.5 203.1 78.9 NS
CWP (mm Hg) 19.7 3.9 23.3  4 .001
VP (mm Hg) 18.4 3.3 23 4.6 .01
Pmax (mm Hg) 689.7 240.8 1025.8 289.4 .001
LWI (mL/kg) 10.6 5.3 12.9  6.2 .01
LWV (mL) 533.2 99.1 614.2 214.6 NS
LA, Interventional lung assist device; CO, cardiac output; NS, not significant; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; SVR,
ystemic vascular resistance; PVR, pulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure; DPmax,
entricular contractibility; ELWI, index extra lung volume water; ELWV, extra lung water volume.
ABLE E2. Hemodynamic differences between direct cannulation or through graft interposition during apneic ventilation
nd interventional lung assist device support
Variables Direct cannulation Graft interposition P value
CO (L/min) 6.8 2.8 9.8 2.7 .02
MAP (mm Hg) 77.3 11.2 79.3 13.8 NS
MPAP (mm Hg) 41 6.9 44 4.0 NS
SVR (dyne/cm5) 912.2 457.8 465.6 213.4 .03
PVR (dyne/cm5) 246.9 65.5 168.1 81.3 .03
PCWP (mm Hg) 23.4 5.6 24  4.7 NS
CVP (mm Hg) 23 6.2 23.5 4.2 NS
DPmax (mm Hg) 1215.4 252.1 812.7 200.5 .01
ELWI (mL/kg) 13.1 7.7 13.1 5.1 NS
ELWV (mL) 748.3 165.3 616.1 176.2 NS
O, Cardiac output; MAP, mean arterial pressure; NS, not significant; MPAP, mean pulmonary arterial pressure; SVR, systemic vascular resistance; PVR,
ulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure; DPmax, ventricular contractibility; ELWI, index
xtra lung volume water; ELWV, extra lung water volume.
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